FTRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Fortrea Holdings Inc (FTRE) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential upside in the long term, as indicated by positive analyst upgrades and a favorable outlook for 2026, the current technical indicators, financial performance, and trading sentiment suggest caution. The stock is oversold, and its recent price drop, combined with weak financials and hedge fund selling, makes it a less compelling buy right now. Waiting for clearer signs of recovery or improved fundamentals would be more prudent.
The stock is currently oversold with an RSI of 12.765, indicating potential for a rebound. However, the MACD is negatively expanding (-0.683), suggesting bearish momentum. The stock is trading near its support level (S1: 10.572), but the overall trend remains weak with converging moving averages.
Multiple analyst upgrades with increased price targets, reflecting optimism about the company's long-term prospects.
Positive sentiment around the company's operational improvements under new leadership.
Favorable outlook for the biopharma cycle and margin recovery in 2026.
Significant price drop in the regular market (-11.39%) and pre-market (-3.71%).
Weak financial performance in Q3 2025, with declining net income (-43.01% YoY) and EPS (-45.16% YoY).
Hedge funds are selling, with a 182.65% increase in selling activity over the last quarter.
Lack of recent news or event-driven catalysts to support a near-term recovery.
In Q3 2025, Fortrea's revenue increased by 3.91% YoY to $701.3M. However, net income dropped significantly by -43.01% YoY to -$15.9M, and EPS fell by -45.16% YoY to -$0.17. Gross margin also declined by -21.93% YoY to 14.7%, indicating deteriorating profitability.
Analysts are cautiously optimistic about Fortrea, with recent upgrades from firms like Truist (Buy, $22 target) and Evercore ISI (Outperform, $25 target). However, some firms like Mizuho maintain a Neutral rating, reflecting mixed sentiment. Analysts highlight improving execution, margin recovery potential, and a favorable 2026 outlook as key positives.
